Clinical Trial Update: A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017 [Phase 1]

View source ↗

Summary

This is a Phase 1 MAD study to evaluate the safety, tolerability and pharmacokinetics of LY03017, with the trial sponsored by Luye Pharma Group Ltd; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Parkinson Disease
• Schizophrenia

Drugs mentioned

• LY03017

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis | Phase 1 | Status: NOT_YET_RECRUITING